TherOx, Inc. Announces Filing of a Registration Statement for Proposed Initial Public Offering of Its Common Stock
Citigroup Global Markets Inc. and UBS Investment Bank are acting as jointbook-running managers for the offering with Cowen and Company, LLC andWachovia Capital Markets, LLC acting as co-managers. The number of shares tobe offered by TherOx and the price range for its shares have yet to bedetermined.
The offering of common stock will be made only by means of a prospectus.When available, a copy of the preliminary prospectus relating to the offeringmay be obtained from either Citigroup Global Markets Inc., Brooklyn ArmyTerminal, 140 58th Street, Brooklyn, New York 11220, Attn: ProspectusDepartment or UBS Investment Bank, Attn: Prospectus Department, 299 ParkAvenue, New York, New York 10171.
A registration statement relating to these securities has been filed withthe Securities and Exchange Commission but has not yet become effective.These securities may not be sold nor may offers to buy be accepted prior tothe time the registration statement becomes effective. This press releaseshall not constitute an offer to sell nor the solicitation of an offer to buynor shall there be any sale of these securities in any state or jurisdictionin which such offer, solicitation or sale would be unlawful prior toregistration or qualification of the securities under the securities laws ofany such state or jurisdiction.
About TherOx, Inc.
TherOx is a medical device company that is focused on designing,developing and marketing products that implement its proprietarySupersaturated Oxygen System to salvage heart muscle in acute heart attackpatients. TherOx's Supersaturated Oxygen System has not yet received FDAapproval and is currently limited by United States law to investigational useonly.Contact: Kevin T. Larkin, (949) 757-1999 President and Chief Executive Officer or Shelley B. Thunen, (949) 757-1999 Chief Financial Officer
SOURCE TherOx, Inc.
You May Also Like